194
Participants
Start Date
November 23, 2020
Primary Completion Date
April 11, 2022
Study Completion Date
April 11, 2022
Dihydroartemisinin-piperaquine
It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
Masafu General Hospital (MGH) at Busia District, Eastern Uganda, Masafu
Baylor-Uganda Center of Excellence on Mulago Hospital Complex and Masafu General Hospital, Kampala
Yale University
OTHER
Makerere University
OTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
University of California, San Francisco
OTHER